Agent Orange Relief Act of 2025

Bill Number

H.R. 3052

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Armed Forces and National Security

Status

Introduced

Latest Action

2025-04-30: Sponsor introductory remarks on measure. (CR H1764)

Last Updated

2026-05-27T08:06:20Z

AI-Generated Summary

Purpose of the Legislation

The Agent Orange Relief Act of 2025 aims to address and remedy the long-term health effects of Agent Orange—a toxic herbicide used by the U.S. military during the Vietnam War (1961–1971). It focuses on providing benefits, research support, health assessments, and assistance to affected U.S. veterans, their children, Vietnamese Americans, and their descendants, while recognizing the broader environmental and generational impacts.

Key Provisions

• Findings and Purpose (Section 2): Outlines historical facts about Agent Orange spraying (e.g., 19 million gallons over Vietnam, Laos, and Cambodia), exposure affecting millions (including 2.1–4.8 million Vietnamese, Lao, and Cambodian people, plus U.S. personnel), associated health issues (e.g., cancers, diabetes, birth defects), and gaps in current U.S. support. Emphasizes ongoing intergenerational effects like epigenetic changes (alterations in gene expression passed down generations without changing DNA).
• Benefits for Children of Male Veterans (Section 3): Expands Department of Veterans Affairs (VA) benefits under Title 38 of the U.S. Code for children born with certain birth defects (e.g., spina bifida, cleft palate, heart defects) to include those of male Vietnam veterans, previously limited to children of female veterans. Includes access to medical records for research on Agent Orange's long-term effects. Effective 30 days after enactment.
• Public Research Support (Section 4): Directs the VA to fund and coordinate research on Agent Orange-related health issues, involving U.S. and international experts (e.g., schools of public health in Vietnam). Requires a survey of children of exposed veterans receiving VA care to assess treatment adequacy and recommend improvements.
• Health Assessments and Assistance for Vietnamese Americans (Section 5): Instructs the Department of Health and Human Services (HHS) to grant funds for health assessments of Vietnamese Americans exposed to Agent Orange (or their descendants) and establish community centers in areas with large Vietnamese American populations for evaluation, counseling, and treatment of related conditions.
• Implementation Deadlines (Section 6): VA and HHS must develop implementation plans within 180 days of enactment and fully implement provisions within 18 months, including issuing requests for proposals where needed.
• Reporting Requirements (Section 7): VA and HHS must submit quarterly reports to Congress starting 18 months after enactment, detailing progress on their respective responsibilities.
• Definition (Section 8): Defines "Agent Orange" broadly to include any herbicides or contaminants (e.g., dioxin, arsenic) used in Vietnam War operations.

Significant Changes to Existing Law

• Amends Subchapter II of Chapter 18 of Title 38, U.S. Code (VA benefits for birth defects), by removing gender-specific language ("woman Vietnam veteran") and making it apply to all Vietnam veterans. This eliminates the prior discrepancy where children of male veterans received limited recognition (only spina bifida) compared to those of female veterans (broader list of defects).
• Adds a new subsection requiring health providers under VA contracts to share medical records for research on Agent Orange's intergenerational effects, enhancing data access for scientific studies.
• Introduces new mandates for HHS to support Vietnamese American communities, which were not previously addressed in federal law.

Potential Impacts

• On Government Agencies: VA and HHS will face increased administrative and funding demands for expanded benefits, research coordination, surveys, grants, and clinic setups. This could require new budgets and partnerships with nonprofits, potentially straining resources but improving health program efficiency through better data.
• On Citizens: U.S. Vietnam veterans and their children gain equitable access to healthcare, compensation, and treatment for Agent Orange-related conditions, addressing unmet needs for disabilities and birth defects. Vietnamese Americans and descendants benefit from targeted assessments and care centers, potentially reducing untreated health issues in immigrant communities.
• On International Relations: While focused domestically, the bill acknowledges spraying in Laos and Cambodia and U.S. remediation efforts in Vietnam (e.g., at airports), which could foster goodwill and cooperation on environmental cleanup and health research with these nations, signaling U.S. responsibility for war legacies.

Main Stakeholders Affected

• U.S. Vietnam Veterans and Families: Particularly male veterans' children with birth defects, who gain expanded VA benefits and research support.
• Vietnamese Americans and Descendants: Communities exposed directly or indirectly, benefiting from HHS-funded assessments and treatment centers.
• Government Entities: VA (benefits and research) and HHS (assessments and clinics), plus congressional oversight committees (e.g., Veterans' Affairs, Energy and Commerce).
• Other Groups: Public health organizations, universities, and NGOs involved in research and implementation; indirectly, affected populations in Vietnam, Laos, and Cambodia through referenced historical context.

Notable Legal, Constitutional, or Political Implications

• Legal: Promotes equity under federal veterans' law by removing gender-based disparities in benefits, aligning with equal protection principles. Enhances research transparency via record-sharing requirements, but includes privacy safeguards implied in VA contracts. No direct challenges to constitutional rights, though implementation may involve rulemaking under the Administrative Procedure Act.
• Constitutional: Supports Congress's authority to provide for veterans' welfare (Article I, Section 8) and general welfare clause, without infringing on states' rights or individual liberties.
• Political: Represents bipartisan acknowledgment of Vietnam War impacts (introduced by Democrats but refers to committees for broad review), potentially advancing reconciliation efforts. Could influence future appropriations debates due to fiscal costs for expanded programs, while highlighting scientific consensus on toxin effects to justify action.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Tlaib, Rashida [D-MI-12]

Cosponsors (16)

Rep. Simon, Lateefah [D-CA-12], Rep. Nadler, Jerrold [D-NY-12], Rep. Thanedar, Shri [D-MI-13], Rep. Carson, André [D-IN-7], Rep. McBride, Sarah [D-DE-At Large], Rep. Moulton, Seth [D-MA-6], Rep. Sánchez, Linda T. [D-CA-38], Rep. Hayes, Jahana [D-CT-5], Rep. Green, Al [D-TX-9], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Chu, Judy [D-CA-28], Rep. Khanna, Ro [D-CA-17], Rep. Cohen, Steve [D-TN-9], Rep. Mullin, Kevin [D-CA-15], Rep. DeSaulnier, Mark [D-CA-10], Rep. DeLauro, Rosa L. [D-CT-3]

Recent Actions

• 2025-04-30: Sponsor introductory remarks on measure. (CR H1764)
• 2025-04-28: Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-04-28: Referred to the Committee on Veterans' Affairs, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-04-28: Introduced in House
• 2025-04-28: Introduced in House

Bill Versions

• Agent Orange Relief Act of 2025 — issued 2025-04-28 — PDF (11 pages)